New Delhi: SOHM, Inc., a globally recognized pharmaceutical company focused on developing, manufacturing and distributing Generic, Branded Generic, Private label, and Sohm-innovated Pharmaceuticals, Cosmeceuticals and Nutraceutical products, announced the approval of a critical patent by the Japan Patent Office (JPO).
This patent safeguards SOHM’s pioneering ABBIE (A Base Binding Integrase Enzyme) genome editing technology, a development poised to significantly impact India’s rapidly evolving biotechnology landscape.
The ABBIE technology represents a substantial advancement in gene editing, offering unprecedented precision and safety that could transform treatment approaches for a range of genetic disorders. As India grapples with a considerable burden of genetic diseases, including sickle cell anaemia, thalassemia, and various forms of genetic cancers, the implementation of this innovative technology stands to provide significant therapeutic advancements for millions of individuals affected by these conditions.
India, home to a significant portion of the global disease burden, particularly genetic disorders, stands to benefit immensely from advancements in gene editing technology. Millions of Indians suffer from conditions like sickle cell anaemia, thalassemia, and various genetic cancers. For instance, it is estimated that over 100,000 children are born with thalassemia major in India each year.
India’s burgeoning biotechnology sector, coupled with increasing government investments and a growing pool of skilled scientists, provides a fertile ground for the application of advanced technologies like gene editing. By fostering collaborations between Indian and international researchers, SOHM aims to accelerate the development of innovative therapies and improve the lives of millions of people.
“We are elated to announce the attainment of this vital patent, which affirms the transformative potential of our ABBIE technology. India, characterized by its substantial patient population and dynamic scientific community, represents an extraordinary opportunity for us to effect meaningful change in global healthcare. Our commitment to partnering with Indian stakeholders underscores our mission to leverage our technology to benefit those in greatest need,” stated David Aguilar Ph.D. COO, SOHM.
SOHM’s ABBIE technology is a groundbreaking approach to gene editing that offers a safer and more precise way to modify the genetic code of organisms.
Gene editing is a technique that allows scientists to change an organism’s DNA, the molecule that carries genetic information. Gene editing leverages molecules to “re-write” the genetic information for numerous uses including advancing therapies for human disease.
Traditional methods often involve creating double-stranded DNA breaks, which can lead to unintended genetic changes. Moreover, traditional methods are limited to the amount of information edited at any given time.